FIELD: chemistry.
SUBSTANCE: in the formula (I) 
, R1 is metoxymethyl; R2 is selected out of -C(O)NR4R5, -SO2NR4R5, -S(O)PR4 and HET-2; R3 is selected out of halogeno, fluoromethyl, metoxy and cyano; HET-1 is 5- or 6-member heteroaryl ring linked by C atom and containing nitrogen atom in 2 position and possibly 1 or 2 additional ring heteroatoms selected independently out of O, N and S, which is possible substituted at available carbon atom or at ring nitrogen atom by 1 substitute selected independently out of R6, provided that it would not cause ring quaternisation. The other radicals are indicated in the invention claim. Also invention refers to pharmaceutical composition containing claimed compound as active component, and methods of obtaining compound of the formula (I).
EFFECT: compounds with glucokinase inhibition effect.
19 cl, 2 tbl, 61 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYLBENZAMYL DERIVATIVES FOR APPLICATION AS GLUCOKINASE (GLK) ACTIVATORS IN TREATMENT OF DIABETES | 2005 |
|
RU2403246C2 |
| NOVEL PHENYL PYRROLE DERIVATIVE | 2009 |
|
RU2470917C2 |
| 3-AMINOPYRROLIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | 2003 |
|
RU2355679C2 |
| AMIDE DERIVATIVES CARRYING CYCLOPROPYLAMINOCARBONYL SUBSTITUTE, SUITABLE AS CYTOKINE INHIBITORS | 2004 |
|
RU2382028C2 |
| N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR TREATING CANCER | 2005 |
|
RU2427572C2 |
| COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | 2008 |
|
RU2443699C2 |
| DERIVATIVES OF HETEROARYLCARBAMOYLBENZENE | 2004 |
|
RU2330030C2 |
| PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | 2013 |
|
RU2658006C2 |
| CATHEPSIN-CYSTEINE PROTEASE INHIBITORS | 2003 |
|
RU2312861C2 |
| AMIDE DERIVATIVES | 2005 |
|
RU2396259C2 |
